The Global Anti-Obesity Drug Market Growth Accelerated By Increased Uptake Of Anti-Obesity Treatment
 |
| Anti-Obesity Drug Market |
Anti-obesity drugs assist in
weight management by suppressing appetite and inhibiting fat absorption. They
provide an alternative to bariatric surgeries for individuals suffering from
obesity and overweight conditions. Containing the twin epidemics of obesity and
diabetes has become a major priority, leading to higher adoption of
anti-obesity medications in clinical practice. The global Anti-Obesity Drug
Market is estimated to be valued at US$ 2542 Mn in 2023 and is expected to
exhibit a CAGR of 20% over the forecast period 2023 to 2030, as highlighted in
a new report published by Coherent Market Insights.
Market key trends:
The increased uptake of anti-obesity
treatment can be attributed to growing awareness and focus on obesity
management. Healthcare providers are actively screening and monitoring obesity
indicators like BMI to identify at-risk patients. Moreover, availability of new
drug formulations targeting different obesity pathways has expanded treatment
options. Drugs suppressing appetite through 5-HT2C receptor agonism or blocking
fat absorption in the gut are emerging as effective alternatives to lifestyle
modification alone. As obesity-related comorbidities place a huge burden on
healthcare systems, treatment guidelines now recommend a combination of diet,
physical activity and FDA-approved anti-obesity pharmacotherapy to facilitate
long-term weight control and management of co-existing conditions like diabetes
and cardiovascular disease.
Segment Analysis
The global anti-obesity drug
market is dominated by weight loss drugs segment. This segment accounts for
over 35% of the market share as weight loss drugs help in reducing appetite and
absorption of fat in the body. They have less side effects when compared with
other options such as bariatric surgery.
Key Takeaways
The Global
Anti-Obesity Drug Market Size is expected to witness high growth. The
global Anti-Obesity Drug Market is estimated to be valued at US$ 2542 Mn in
2023 and is expected to exhibit a CAGR of 20% over the forecast period 2023 to
2030.
North America is expected to
remain the largest and fastest growing regional market for anti-obesity drugs
during the forecast period. High obesity rates and strong presence of key
players are major factors driving the market in the region.
Key players operating in the anti-obesity drug market are GE
Healthcare, R1 RCM, Inc. (Accretive Health), Allscripts Healthcare Solutions,
Inc., Kareo, Inc., Cerner Corporation, Quest Diagnostics, and Experian
Information Solutions, Inc., among others. Major players are continuously
focusing on new product development and introduction of generic drugs to
increase their market share.
Get More Insights Here
https://www.newsstatix.com/anti-obesity-drug-market-size-share-growth-outlook-2023/
Comments
Post a Comment